Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (494)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02030964 | N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan(DFMO) | completed | Phase 1 | 30 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 3 | Feb 17, 2025 | clinicaltrials |
| NCT03481231 | In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma(IMMUNOGLIO) | completed | — | 160 | Centre Georges Francois LeclercOTHER |
| 2 |
| Feb 17, 2025 |
| clinicaltrials |
| NCT03576612 | GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas(GMCI) | completed | Phase 1 | 41 | Candel Therapeutics, Inc.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05140902 | Accurate DCE-MRI Measurement of Glioblastoma Using Point-of-care Portable Perfusion Phantom | completed | N/A | 12 | University of Alabama at BirminghamOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04023669 | Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | completed | Phase 1 | 21 | St. Jude Children's Research HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03213691 | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 2 | Feb 5, 2025 | clinicaltrials |
| NCT02078648 | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 74 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT03495960 | Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System(FIORELLA) | completed | Phase 2 | 72 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 4 | Jan 30, 2025 | clinicaltrials |
| NCT06469138 | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects(8479217) | completed | Phase 1 | 6 | BerGenBio ASAINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT03154190 | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | completed | N/A | 128 | Stanford UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT02020720 | 18F-DOPA-PET in Planning Surgery in Patients With Gliomas | completed | Early Phase 1 | 72 | Mayo ClinicOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT02960230 | H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | completed | Phase 1 / Phase 2 | 50 | Sabine Mueller, MD, PhDOTHER | 2 | Jan 22, 2025 | clinicaltrials |
| NCT05296122 | Safety and Feasibility of MR-guided Laser Thermal Ablation of Brain Lesions | completed | N/A | 14 | Clinical Laserthermia Systems ABINDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT02323880 | Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | completed | Phase 1 | 59 | Children's Oncology GroupNETWORK | 1 | Jan 14, 2025 | clinicaltrials |
| NCT02465268 | Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme(ATTAC-II) | completed | Phase 2 | 175 | University of FloridaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03914742 | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations | completed | Phase 1 / Phase 2 | 67 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04842513 | Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma(GLIO-XS15) | completed | Phase 1 | 15 | University Hospital TuebingenOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT01849146 | Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma | completed | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04280848 | Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma(UCPVax-Glio) | completed | Phase 2 | 67 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04841434 | A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL(VALIDATE) | completed | Phase 1 / Phase 2 | 18 | Charite University, Berlin, GermanyOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT02076906 | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | completed | Phase 1 | 7 | AeRang KimOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT01752491 | A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme | completed | Phase 1 | 13 | Joseph J. Cullen, MD, FACSOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04428879 | Topotecan Episcleral Plaque for Treatment of Retinoblastoma(STEP-RB) | completed | Phase 1 | 26 | The Hospital for Sick ChildrenOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT05015543 | Physical Training in Glioblastoma Patients During Cytotoxic Therapy(MMH) | completed | N/A | 54 | University Hospital MuensterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01464177 | Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme(GBM Hypo RT) | completed | Phase 2 | 40 | Andre Tsin Chih ChenOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06557967 | Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment | completed | — | 22,517 | Daiichi SankyoINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01130077 | A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas | completed | Phase 1 | 60 | James FelkerOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT04109209 | Psychological Intervention For Brain Tumor Caregivers | completed | N/A | 120 | Massachusetts General HospitalOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04726397 | UNIty-Based MR-Linac Guided AdapTive RadiothErapy for High GraDe Glioma: a Phase 2 Trial(UNITED) | completed | N/A | 108 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT02549833 | Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma | completed | Phase 1 | 28 | Jennie TaylorOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT04217694 | Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors | completed | Early Phase 1 | 18 | Mayo ClinicOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT00002730 | Chemotherapy in Treating Children With Neuroblastoma | completed | Phase 1 | — | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03232424 | NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma | completed | Phase 1 | 12 | Hackensack Meridian HealthOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05062772 | Brain Tumor Intraoperative Ultrasound Database(BraTioUS-DB) | completed | — | 150 | Hospital del Rio HortegaOTHER | 5 | Nov 15, 2024 | clinicaltrials |
| NCT03865355 | Blood and Cerebrospinal Fluid Metabolomic Profile in Glioma Patients | completed | — | 50 | Novosibirsk State UniversityOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03735498 | Psychological Intervention for Caregivers of Patients With Malignant Gliomas | completed | N/A | 13 | Massachusetts General HospitalOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT03732352 | 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma | completed | Phase 2 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04845919 | Sonodynamic Therapy With ExAblate System in Glioblastoma Patients(Sonic ALA) | completed | Phase 2 | 5 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT02101905 | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Nov 6, 2024 | clinicaltrials |
| NCT00695279 | Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products | completed | — | 41 | St. Jude Children's Research HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT03922984 | Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Glioblastoma | completed | N/A | 43 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT05427214 | Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy(Dragon) | completed | N/A | 52 | Washington University School of MedicineOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT04304300 | Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes(RIGEL) | completed | — | 80 | Erasmus Medical CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03926507 | F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery | completed | N/A | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 17, 2025source: clinicaltrials